Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

585 results

• High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin’s Lymphoma or Central Nervous System (CNS) Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 30NCT01182415
• High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML: Complete Statistical AnalysisIndependent statistical analysis of High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00774046).Phase 2Results postedn = 32NCT00774046
• High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00349778).Phase 2Results postedn = 102NCT00349778
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 20NCT01434472
• Home Based Daratumumab Administration for Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Home Based Daratumumab Administration for Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05511428).Phase 4Results postedn = 20NCT05511428
• Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 10NCT00547365
• HUPKIndependent statistical analysis of Pharmacokinetics of Oral Hydroxyurea Solution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03763656).Phase 1/2Results postedn = 33NCT03763656
• Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 19NCT02997761
• Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 32NCT02315768
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 23NCT02869633
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 28NCT02824029
• Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 20NCT02207062
• ICT-HCTIndependent statistical analysis of Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 50NCT01812252
• Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: Complete Statistical AnalysisIndependent statistical analysis of Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 40NCT01426828
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 10NCT02258529
• IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients: Complete Statistical AnalysisIndependent statistical analysis of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02854059).Phase 2Results postedn = 2NCT02854059
• IKEMAIndependent statistical analysis of Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 302NCT03275285
• IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia: Complete Statistical AnalysisIndependent statistical analysis of IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00524342).Phase 2Results postedn = 7NCT00524342
• IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: Complete Statistical AnalysisIndependent statistical analysis of IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 33NCT01885897
• Imaging in MGUS, SMM and MM: Complete Statistical AnalysisIndependent statistical analysis of Imaging in MGUS, SMM and MM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01237054).Phase 2Results postedn = 31NCT01237054
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 32NCT00509093
• Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 100NCT05460013
• Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 22NCT01269385
• INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 15NCT03837509
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia: Complete Statistical AnalysisIndependent statistical analysis of Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 123NCT03238911
• Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis: Complete Statistical AnalysisIndependent statistical analysis of Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 1NCT04438382
• Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease: Complete Statistical AnalysisIndependent statistical analysis of Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 196NCT00760435
• Influenza Vaccine Post Allogeneic Transplant: Complete Statistical AnalysisIndependent statistical analysis of Influenza Vaccine Post Allogeneic Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01215981).Phase NAResults postedn = 68NCT01215981
• Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes: primary endpoint results,…Phase 2Results postedn = 31NCT03399773
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 60NCT04850846
• Ipilimumab and Local Radiation for Selected Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Ipilimumab and Local Radiation for Selected Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01769222).Phase 1Results postedn = 3NCT01769222
• IRISAn independent statistical analysis of the randomized phase 3 IRIS trial evaluating Follitropin Delta (FE 999049) versus Follitropin Alfa (GONAL-F) for controlled ovarian stimulation in Indian women with infertility.Phase 3n = 220NCT04773353
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA): Complete Statistical AnalysisIndependent statistical analysis of Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1,512NCT02940886
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,538NCT02940860
• Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients: Complete Statistical AnalysisIndependent statistical analysis of Iron Sucrose in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00721188).Phase 2Results postedn = 11NCT00721188
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation: primary endpoint…Phase 2Results postedn = 59NCT04339101
• ITPIndependent statistical analysis of Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00699140).Phase 3Results postedn = 18NCT00699140
• Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 165NCT01415882
• Japanese AMLIndependent statistical analysis of Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 9NCT03135028
• JETiIndependent statistical analysis of JETi Lower Extremity Arterial Thrombosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04370691).Phase NAResults postedn = 129NCT04370691
• JULIETIndependent statistical analysis of the JULIET phase 2 study of tisagenlecleucel in adults with diffuse large B-cell lymphoma, covering trial design, the registry-defined overall response endpoint, planned statistical analysis, safety, interpretation, and…Phase 2Results postedn = 115NCT02445248
• KarMMa-3Independent statistical analysis of the randomized phase 3 KarMMa-3 trial of bb2121 versus standard regimens in relapsed and refractory multiple myeloma, including its progression-free survival endpoint, trial design, statistical methodology, and planned…Phase 3n = 386NCT03651128
• KEM-VOCIndependent statistical analysis of Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02434939).Phase 4Results postedn = 240NCT02434939
• KetoPltAggIndependent statistical analysis of IV Ketorolac on Platelet Function Post-Cesarean Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03805607).Phase 4Results postedn = 40NCT03805607
• Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 9NCT02770820
• LAL1610Independent statistical analysis of Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 35NCT01462253
• LASORIndependent statistical analysis of Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 191NCT00802841
• LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.: Complete Statistical AnalysisIndependent statistical analysis of LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 163NCT00517413
• Learning Impairments Among Survivors of Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Learning Impairments Among Survivors of Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576472).Phase 4Results postedn = 469NCT00576472
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 10NCT02301936

← All therapeutic areas